LYRA
Income statement / Annual
Last year (2024), Lyra Therapeutics, Inc.'s total revenue was $1.53 M,
a decrease of 1.54% from the previous year.
In 2024, Lyra Therapeutics, Inc.'s net income was -$93.44 M.
See Lyra Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
| Operating Revenue |
$1.53 M |
$1.56 M |
$1.36 M |
$285,000.00 |
$0.00 |
$0.00 |
$1.24 M |
| Cost of Revenue |
$0.00
|
$0.00
|
$1.07 M
|
$1.00 M
|
$95,000.00
|
$27,000.00
|
$0.00
|
| Gross Profit |
$1.06 M
|
$1.56 M
|
$296,000.00
|
-$716,000.00
|
-$95,000.00
|
-$27,000.00
|
$1.24 M
|
| Gross Profit Ratio |
0.69
|
1
|
0.22
|
-2.51
|
0
|
0
|
1
|
| Research and Development Expenses |
$43.77 M
|
$48.03 M
|
$38.80 M
|
$29.69 M
|
$12.52 M
|
$12.03 M
|
$4.98 M
|
| General & Administrative Expenses |
$18.50 M
|
$19.06 M
|
$17.56 M
|
$14.21 M
|
$9.69 M
|
$4.49 M
|
$3.53 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$18.50 M
|
$19.06 M
|
$17.56 M
|
$14.21 M
|
$9.69 M
|
$4.49 M
|
$3.53 M
|
| Other Expenses |
$35.62 M
|
$0.00
|
$1.32 M
|
$0.00
|
$0.00
|
$0.00
|
$1.19 M
|
| Operating Expenses |
$97.88 M
|
$68.68 M
|
$56.35 M
|
$43.90 M
|
$22.21 M
|
$16.52 M
|
$8.50 M
|
| Cost And Expenses |
$97.88 M
|
$68.68 M
|
$56.35 M
|
$43.90 M
|
$22.21 M
|
$16.52 M
|
$8.50 M
|
| Interest Income |
$2.95 M
|
$4.50 M
|
$1.04 M
|
$102,000.00
|
$82,000.00
|
$213,000.00
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
$524,000.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$471,000.00
|
$278,000.00
|
$1.07 M
|
$1.00 M
|
$95,000.00
|
$27,000.00
|
$82,000.00
|
| EBITDA |
-$60.26 M |
-$65.25 M |
-$53.92 M |
-$42.61 M |
-$22.11 M |
-$16.49 M |
-$7.18 M |
| EBITDA Ratio |
-39.28
|
-41.88
|
-39.56
|
-149.52
|
0
|
0
|
-5.77
|
| Operating Income Ratio |
-62.81
|
-43.08
|
-41.31
|
-153.04
|
0
|
0
|
-5.84
|
| Total Other Income/Expenses Net |
$2.95 M
|
$4.50 M
|
$1.04 M
|
$102,000.00
|
$82,000.00
|
$213,000.00
|
$1.23 M
|
| Income Before Tax |
-$93.40 M
|
-$62.62 M
|
-$55.27 M
|
-$43.51 M
|
-$22.13 M
|
-$16.31 M
|
-$6.03 M
|
| Income Before Tax Ratio |
-60.88
|
-40.19
|
-40.55
|
-152.68
|
0
|
0
|
-4.85
|
| Income Tax Expense |
$39,000.00
|
$59,000.00
|
$13,000.00
|
-$1.10 M
|
-$82,000.00
|
-$213,000.00
|
-$1.23 M
|
| Net Income |
-$93.44 M
|
-$62.68 M
|
-$55.28 M
|
-$42.41 M
|
-$22.05 M
|
-$16.09 M
|
-$6.03 M
|
| Net Income Ratio |
-60.91
|
-40.23
|
-40.56
|
-148.81
|
0
|
0
|
-4.85
|
| EPS |
-71.5 |
-63 |
-91.5 |
-163.5 |
-128.5 |
-62.5 |
-48 |
| EPS Diluted |
-71.5 |
-63 |
-91.5 |
-163.5 |
-128.5 |
-62.5 |
-48 |
| Weighted Average Shares Out |
$1.30 M
|
$996,080.00
|
$604,720.00
|
$259,720.00
|
$171,800.00
|
$258,500.00
|
$125,320.00
|
| Weighted Average Shares Out Diluted |
$1.30 M
|
$996,080.00
|
$604,720.00
|
$259,720.00
|
$171,800.00
|
$258,500.00
|
$125,320.00
|
| Link |
|
|
|
|
|
|
|
